Ninlaro (ixazomib capsules – Takeda) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Ninlaro will be taken in combination with lenalidomide or cyclophosphamide and dexamethasone OR Patient has received at least one prior regimen for multiple myeloma OR The medication will be used following hematopoietic stem cell transplantation OR BOTH of the following: (a) According to the prescriber, the patient is not a candidate for bortezomib or Kyprolis (carfilzomib intravenous infusion); AND (b) Patient is not a transplant candidate

Approval duration

1 year